Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SATURN secukinumab in psoriatic arthritis
ISRCTN16488621Phase 2Completed
- Sponsor
- University of Liverpool
- Start
- Oct 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, open-label trial of secukinumab in psoriatic arthritis (PsA) (3 arms), sponsored by University of Liverpool. Primary endpoints: Neutrophil phenotype at 12 months, Neutrophil lifespan at 12 months and 1 more. Started Oct 2016; status: completed.
02
Drugs
secukinumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on ISRCTN16488621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN16488621.